Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism

American Journal on Addictions

Volumn 23, Issue 2, 2014, Pages 137-144

  McCance Katz, Elinore F ^a   Gruber, Valerie A ^a   Beatty, George ^a   Lum, Paula ^a   Ma, Qing ^b   Difrancesco, Robin ^b   Hochreiter, Jill ^b   Wallace, Paul K ^c   Faiman, Morris D ^d   Morse, Gene D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BENZOXAZINE DERIVATIVE; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; EFAVIRENZ; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RITONAVIR; S-METHYL DIETHYLTHIOCARBAMATE; S-METHYL N,N-DIETHYLTHIOLCARBAMATE SULFOXIDE; THIOCARBAMIC ACID DERIVATIVE;

ADULT; AGONISTS; ALCOHOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; FEMALE; HALF LIFE TIME; HUMAN; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; ALDEHYDE DEHYDROGENASE; ANTI-HIV AGENTS; ATAZANAVIR SULFATE; BENZOXAZINES; BIOTRANSFORMATION; DISULFIRAM; DITIOCARB; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHANOL; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; THIOCARBAMATES;

EID: 84893875506     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.12081.x     Document Type: Article

References (38)

1. Wright C, Moore RD., Disulfiram treatment of alcoholism. Am J Med. 1990; 88: 647-655. (Pubitemid 20192282)
2. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: A half a century later. J Clin Psychopharmacol. 2006; 26: 290-302. (Pubitemid 43804621)
3. Barth KS, Malcolm RJ., Disulfiram: An old therapeutic with new applications. CNS Neurol Disord Drug Targets. 2010; 9: 5-12.
4. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized, placebo-controlled, clinical trial. Arch Gen Psychiatry. 2004; 61: 264-272. (Pubitemid 38295828)
5. Baker JR, Jatlow P, McCance-Katz EF., Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007; 87: 202-209. (Pubitemid 46215924)
6. Drug-Associated HIV Transmission Continues in the United States. Centers for Disease Control and Prevention. 2007; http://www.cdc.gov/hiv/resources/ factsheets/idu.htm. Accessed 24 October 2012.
7. Green TC, Kershaw T, Lin H, et al. Patterns of drug use and abuse among aging adults with and without HIV: A latent class analysis of a US Veteran cohort. Drug Alcohol Depend. 2010; 110: 208-220.
8. Metzger DS, Zhang Y., Drug treatment as HIV prevention: Expanding treatment options. Curr HIV/AIDS Rep. 2010; 7: 220-225.
9. Bonacini M., Alcohol use among patients with HIV infection. Ann Hepatol. 2011; 10: 502-507.
10. Samet JH, Horton NJ, Meli S, et al. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004; 28: 572-577. (Pubitemid 38506891)
11. Braithwaite RS, Conigliaro J, Roberts MS, et al. Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care. 2007; 19: 459-466. (Pubitemid 46598742)
12. Madan A, Faiman MD., Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram. J Pharmacol Exp Ther. 1995; 272: 775-780.
13. Madan A, Parkinson A, Faiman MD., Role of flavin-dependent monooxygenases and cytochrome P450 enzymes in the sulfoxidation of S-methyl N,N-diethylthiolcarbamate. Biochem Pharmacol. 1993; 46: 2291-2297. (Pubitemid 24012322)
14. Madan A, Parkinson A, Faiman MD., Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N- diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram. Drug Metab Dispos. 1995; 23: 1153-1162.
15. Madan A, Parkinson A, Faiman MD., Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: Role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998; 22: 1212-1219. (Pubitemid 28443143)
16. Kharasch ED, Hankins DC, Jubert C, et al. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: Evidence for specificity toward P-450 2E1. Drug Metab Dispos. 1999; 27: 717-723. (Pubitemid 29252447)
17. Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 1989; 45: 476-486. (Pubitemid 19155025)
18. Enghusen Poulsen H, Loft S, Andersen JR, et al. Disulfiram therapy: Adverse drug interactions and interactions. Acta Psychiatr Scand Suppl. 1992; 369: 359-366.
19. Poulsen HE, Ranek L, Jorgensen L., The influence of disulfiram on acetaminophen metabolism in man. Xenobiotica. 1991; 21: 243-249.
20. Honjo T, Netter KJ., Inhibition of drug demethylation by disulfiram in vivo and in vitro. Biochem Pharmacol. 1969; 18: 2681-2683.
21. Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004; 44: 1273-1281. (Pubitemid 39391486)
22. Sustiva (efavirenz) capsules and tablets package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020972s038lbl.pdf. Accessed 1 November 2012.
23. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996; 277: 423-431. (Pubitemid 27169089)
24. Sheehan DV, Lecrubier Y, Sheehan HK, et al. The mini-international neuropsychiatric interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 (Suppl. 20): 22-33. (Pubitemid 29001829)
25. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. Nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006; 43 (Suppl. 4): S224-S234. (Pubitemid 44901890)
26. Povsic TJ, Zavodni KL, Kelly FL, et al. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol. 2007; 50: 2243-2248. (Pubitemid 350166817)
27. Hochreiter J, McCance-Katz EF, Lapham J, et al. Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 897: 80-84.
28. Keil K, Frerichs VA, DiFrancesco R, et al. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit. 2003; 25: 340-346. (Pubitemid 36638180)
29. Keil K, Hochreiter J, DiFrancesco R, et al. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: Validation and application. Ther Drug Monit. 2007; 29: 103-109. (Pubitemid 46279883)
30. Peachey JE, Brien JF, Roach CA, et al. A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide. J Clin Psychopharmacol. 1981; 1: 21-26. (Pubitemid 12235536)
31. Freundt KJ., Variable inhibition of human hepatic drug metabolizing enzymes by disulfiram. Int J Clin Pharmacol Biopharm. 1978; 16: 323-330. (Pubitemid 8373365)
32. Reyataz (atazanavir sulfate) capsules package insert. Available at: http://packageinserts.bms.com/pi/pi-reyataz.pdf. Accessed 11 November 2012.
33. Perloff ES, Duan SX, Skolnik PR, et al. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005; 33: 764-770. (Pubitemid 40686629)
34. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005; 33: 1729-1739. (Pubitemid 41539973)
35. Bristol Myers Squibb. Reyataz (atazanavir) prescribing information. Physicians' desk reference pp 3299-3310. 2009.
36. Faiman MD, Jensen JC, Lacoursiere RB., Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther. 1984; 36: 520-526. (Pubitemid 15201164)
37. Baker JR, Jatlow P, McCance-Katz EF., Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2000; 87: 202-209.
38. Bode H., Systematic studies on the application of diethyl dithiocarbamate in analysis. Chem 1954; 142: 414.